News
EAC Embarks On Multi-Million Medicine Project
13 May 2013
The East African Community (EAC) has kicked off the implementation of the EAC Regional Pharmaceutical Manufacturing Plan of Action (EACPMPOA 2012-2016) by setting up a project steering committee comprising players from partner states. According to ...
Click on the link to read the full article at AllAfrica.com (This link will open in a new window)Pharmaceutical giants used Communist East Germany for 'illegal' trials
13 May 2013
Pharmaceutical companies paid millions of pounds to former Communist East Germany to use more that 50,000 patients in state-run hospitals as unwitting guinea pigs for drug tests in which several people died, it was revealed today.
Click on the link to read the full article at Belfast Telegraph (This link will open in a new window)Kashmir-based pharmaceutical company eyeing Kazakhstan market
12 May 2013
The company recently received a high-level delegation from Kazakhstan. Led by Head, Pharmaceutical Assessment Department, Kazakhstan, Ardak U Tulegenova, the delegation inspected the Protech Biopharma Private Limited, the only manufacturing unit ...
Click on the link to read the full article at GreaterKashmir.com (This link will open in a new window)Downgrade expected to negatively impact pharmaceutical industry: Experts
12 May 2013
The downgrading of Egypt's sovereign rating, by Moody's to CAA1 and Standard & Poor's to B-, will ultimately raise the cost of pharmaceuticals in Egypt due to the affect of the country's credit score on the financial costs of credit and foreign ...
Click on the link to read the full article at Daily News Egypt (This link will open in a new window)New Market Research Report: PharmaSphere: Global Generics Strategy - Key ...
11 May 2013
GlobalData's "PharmaSphere: Global Generics Strategy - Key Drivers, Markets and Trends in 2013" report, provides strategic analysis of the global generics industry. It discusses key trends, significant M&A deals in 2012, and describes the operations ...
Click on the link to read the full article at SBWire (press release) (This link will open in a new window)Positive Prognosis for Biotech ETFs
10 May 2013
The biotechnology sector has positive long term implications and the indecision that loomed over the industry has subsided, according to S&P Capital. Exchange traded funds that track this sector are a sound choice for risk mitigation while gaining ...
Click on the link to read the full article at ETF Trends (This link will open in a new window)Nano Labs Develops Nano Biotechnology Mesh That Can Help Doctors Dress ...
10 May 2013
DETROIT, May 10, 2013 (GLOBE NEWSWIRE) -- Nano Labs Corp. (OTCQB:CTLE) is pleased to announce today it has developed an innovative hemostatic material which it has filed for provisional patent and is currently presenting to the biomedical industry.
Click on the link to read the full article at NASDAQ (press release) (This link will open in a new window)Another Good Report Card For Biotechnology High
10 May 2013
The good grades continue to come in at Biotechnology High School as the second national magazine rated the Momouth County Vocational School District academy one of the country's top high schools. Newsweek magazine's annual rating of high schools ...
Click on the link to read the full article at Patch.com (This link will open in a new window)Charity to link with pharmaceutical
10 May 2013
London - International development charity Save the Children is linking up with British pharmaceutical giant GlaxoSmithKline in what both sides say is a unique collaboration to save children's lives in Africa. GSK will provide
Click on the link to read the full article at eNCA (This link will open in a new window)An end to generic claims for innovator profits?
10 May 2013
Until January 2013, the law of generic claims under section 8 of the Patent Medicines (Notice of Compliance) Regulations (the ?NOC Regulations?) differed depending on the court chosen by the generic. Federal Court jurisprudence had clearly prohibited ...
Click on the link to read the full article at Lexology (registration) (This link will open in a new window)
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
